BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to invest in. On November 13, BMO Capital initiated coverage of BrightSpring Health with an Outperform rating and $40 price target. BMO Capital maintains its three-year outlook for BrightSpring to achieve 12%+ EBITDA growth, driven by multiple factors. The firm anticipates a long-term opportunity for BrightSpring to secure additional limited distribution drug contracts and benefit from an increase in generic drug conversions. Ea ...

Core Viewpoint - BrightSpring Health Services Inc. (NASDAQ:BTSG) is identified as a strong growth stock under $30, with a recent price target increase from BofA to $31, maintaining a Buy rating despite concerns over a more negative policy and reimbursement environment [1][3]. Financial Performance - In Q2 2025, BrightSpring Health reported total revenue of $3.1 billion, reflecting a 29% year-over-year increase [2]. - Adjusted EBITDA also increased by 29% to $143 million, while the EBITDA margin remained flat at 4.5% compared to the previous year [2]. - Gross profit for the quarter was $375 million, marking a 20% increase [2]. Segment Performance - The Pharmacy Solutions segment was the main growth driver, with revenue rising 32% year-over-year to $2.8 billion [3]. - Infusion and Specialty Revenue within this segment saw a significant 39% increase, reaching $2.2 billion, while specialty scripts grew by 38% [3]. - Home & Community Pharmacy Revenue grew by 11% to $587 million, contributing to the overall growth in gross profit per script [3]. Company Overview - BrightSpring Health Services operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4].

Company Overview - BrightSpring Health Services Inc. (NASDAQ:BTSG) operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4]. Financial Performance - In Q2 2025, BrightSpring Health reported total revenue of $3.1 billion, reflecting a 29% year-over-year growth, primarily driven by the Pharmacy Solutions segment [2][3]. - The Pharmacy Solutions segment experienced a 32% increase in revenue, reaching $2.8 billion, with infusion and specialty revenue surging by 39% to $2.2 billion and specialty scripts growing by 38% [2][3]. - The Provider Services segment contributed to growth with an 11% revenue increase to $358 million, supported by home healthcare revenue rising 17% to $185 million, rehab revenue increasing by 9% to $73 million, and personal care revenue growing by 4% to $100 million [3]. - Overall gross profit for the company increased by 20% year-over-year to $375 million [3]. Analyst Ratings - Deutsche Bank analyst Pito Chickering raised the price target for BrightSpring Health to $30 from $25 while maintaining a Buy rating on the shares [1][3].